Tag Archives: entrepreneurs

Calling All Life Science Entrepreneurs – Enter the RESI Boston Innovation Challenge

13 Jul

By Chris Cummings, Senior Business Development Manager, LSN

Christine A. Wu, Senior Research Analyst, LSN

chrsitineRESI is coming home to Boston and so is the RESI Innovation Challenge. This September’s life science innovation competition will showcase the most promising new health technologies in the RESI Innovation Challenge. If you are fundraising and aim to build a presence in the Boston’s booming healthcare scene, we’d like to see your application.

The RESI Innovation Challenge invites the top-tier early-stage companies in therapeutics, medical devices, diagnostics and healthcare IT to present from around the globe. All applicants will be vetted on the crucial balance of the quality of the company’s scientific innovation and the investment potential based on the company current standings and management team.

On September 26th, RESI’s estimated 1000 attendees will receive “RESI Cash” to “invest” in the company whom they believe to be the most “investible” of the contestants. The top three winners with the most RESI cash will receive prizes and be featured in our RESI newsletter recap that will go out to LSN’s 20,000 newsletter readership.

In the past we have seen around 50% of Innovation Challenge companies receive funding within a year from their exhibition at RESI. Be sure not to miss out on the chance of adding to this statistic – apply for the Innovation Challenge.

See below for the previous RESI Innovation Challenge testimonials.

“RESI Innovation Challenge was a fantastic way for us to increase exposure to investors attending the event. We highly recommend leveraging the Innovation Challenge with the one-on-one partnering platform to get more face time with investors.”

– Herman Lo, CEO, ViewsIQ Inc.

3rd Place in San Diego IC


“It was an absolute pleasure to participate in the RESI conference held at MaRS in Toronto. The unique structure of the conference facilitated creating new relationships with potential investors and partners. In particular, the Innovation Challenge pushed us to introduce ourselves to new people, which will be useful as we look towards a future financing round. I definitely recommend the RESI conferences to entrepreneurs seeking financing in the bio / health space.”
– Raymond Shih, President, Co-Founder, QoC Health
3rd Place, RESI on MaRS, June 23, 2016


“The RESI Innovation Challenge is a really good opportunity to meet investors and other companies in the space.  It’s a good showcase to reach that audience.”

– Jessica Ching, CEO, Eve Medical

2nd Place, RESI San Francisco, January 12, 2016

“The RESI Innovation Challenge is a unique way to pitch, and provides a great opportunity to see what other companies are doing in the industry, while allowing you to meet with potential investors and strategic partners outside of the partnering meetings.”

– John Connolly, VP Corporate Development, Rna Diagnostics

1st Place, RESI Boston, September 16, 2015

1:1 Ratio of Entrepreneurs to Investors at Upcoming RESI Event

15 Jun

By Natasha Eldridge, RESI Conference Manager, LSN

natasha-wp-newHow do you get the most out of a day of networking and one-to-one meetings? It’s all about being able to connect with the right partners. At RESI, hundreds of highly innovative early stage companies in drug development, medical devices, diagnostics and healthcare IT come to meet with hundreds of early stage investors focused on those verticals. RESI gathers attendees from not just all over North America, but all over the world. The investors in attendance are very diverse, representing both traditional funding sources like venture capital firms and large pharmas, and also newer sources in early stage investment such as family offices and nonprofit foundations. Via RESI’s uniquely curated Partnering system, attendees can zero in on the most relevant potential investors and ensure that their meetings will have a strong basis in mutual fit. Want to take part?

Register here now

RESI Partnering Opens Monday 5/22 – The Early Entrepreneur Gets the Meetings

18 May

By Michael Quigley, VP of Market Research, LSN

mike-2RESI Partnering goes live on Monday, enabling fundraising life science executives and the investors who fund them to request meetings with one another on the basis of mutual fit. By getting into the system on day one you have the opportunity of being the first to request meetings, thus increasing your chances of being considered and getting the best meetings possible.

Powered by LSN’s proprietary investor data, the RESI partnering platform offers you something no other conference provider can, qualified forward-looking data on what investors are looking for. This data is one of several ingredients in RESI’s secret sauce that enables us to make so many meaningful connections (over 1500 per event!) between fundraising executives and investors.

Just getting in early isn’t enough to secure the most meaningful meetings as possible. We have been studying our partnering analytics since RESI 1, and after 12 RESI events we have proved that….big surprise….the more meeting requests you send out, the more meetings you will secure. The chart below shows the relationship between requests sent and meetings confirmed at a previous RESI event. Science and data minded folks, see for yourself!

And if all that isn’t enough to get you sign up, note that if you sign up by Friday May 19th you can beat the $200 price increase. I hope to see you all buzzing in the partnering hall in San Diego this June 19th.

Click Here to Register Now

Understanding your Therapeutic Asset’s Landscape

20 Nov

By Alejandro Zamorano, VP of Business Development, LSN

Most early stage biotech assets have the potential to target several disease areas. However, it is critical for entrepreneurs to maintain focus in a specific area – this helps to efficiently bring a product to market, and to show investors a firm commitment to a specific goal. But how do you choose which indication to pursue? Of course, there are advantages surrounding orphan drug regulation, hot disease areas, and other major factors. However, one area that many entrepreneurs do not investigate thoroughly is the early stage competitive landscape in their target indication area. This should, however, be a consideration in any entrepreneur’s mind.

This article seeks to offer a 30,000-foot view of the therapeutic landscape, based on a sample of over 14,000 therapeutic assets. As demonstrated by the graphic below, there is a dense concentration of therapeutic assets in a select few disease areas. In fact, the top 3 main indications represent over 50% of all therapeutic assets currently being developed. This high concentration means that differentiating your asset will potentially be more challenging.

Number of Therapeutic Assets by Disease Area

Screen shot 2013-11-20 at 12.51.39 PM (2)Click to enlarge

Competition will surface not only in the form of showing clinical significance, but also in the fundraising process. However, on a positive note, the clinical path for development should be much clearer, as companies have most likely traversed the same regulatory path your therapeutic is now embarking on. Learning from your competitors always pays dividends.

At the end of the day, you know your asset best, and how you fit into the competitive landscape. What is true for one company may not be true for another, but it is undeniable that every company looking to commercialize an asset needs to understand the therapeutic landscape and how to maneuver it most effectively.

%d bloggers like this: